Osteoporosis and Translational Research
Our research is focussed on the epidemiology of osteoporosis, defining optimal treatment pathways and identifying novel genetic pathways that influence osteoporosis risk.
We have shown the much higher than recognised prevalence of this problem and its association with ill-health, health care costs and premature death. We have also shown that specific treatment can reduce the risk of premature death.
Our Dubbo Osteoporosis Epidemiology Study over nearly 25 years has provided major insights into the osteoporosis problem and remains the longest running study of osteoporosis in men and women world-wide.
We continue to focus on ways of improving care and identifying novel pathways as targets for new treatments.
In the News
Australians across the generations at risk with weak understanding of osteoporosis - Oct 20, 2015
Professors Mattick and Eisman inducted into Australian Academy of Health and Medical Sciences - Apr 07, 2015
Garvan receives $15.5 million in NHMRC funding round - Oct 25, 2013
Professor John Eisman wins ASBMR William F. Neuman Award - Jun 21, 2013
International consensus on 'secondary fracture prevention' - Aug 01, 2012
A step towards preventing ‘bone failure’ in Australia - Nov 07, 2011
An extra 5 years of life an unexpected benefit of osteoporosis treatment - Feb 03, 2011
Why measuring absolute risk of fracture could save many broken bones - Jul 28, 2009
Low Vitamin D causes problems for acutely ill patients - Apr 30, 2009
Genotyping takes us closer to an osteoporosis fingerprint - May 01, 2008
Web-based tool to predict risk of bone fracture - Mar 07, 2008